MEXICO CITY — The World Health Organization (WHO) announced its updated recommendation for pre-exposure prophylaxis (PrEP) to include event-driven PrEP taken before and after sex – also called on-demand PrEP – as an HIV prevention option for men who have sex with men.
According to AIDSMap, the pdate was announced at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City.
AIDSMap reported that event-driven PrEP involves taking a double dose (two pills) of Truvada (tenofovir disoproxil fumarate/emtricitabine) between 2 and 24 hours before sex is anticipated, and then, if sex occurs, one pill 24 hours after the double dose and another 24 hours later. If sex occurs several days in a row, one pill should be taken each day, until 48 hours after the last event.
In 2015, Dr Jean-Michel Molina of the University of Paris reported that event-driven PrEP reduced the risk of HIV infection by 86% among gay and bisexual men in the French Ipergay study – equalling the protective effect of daily PrEP in the UK PROUD study, the medical news website reported.
Following Ipergay, Molina’s group embarked on the Prévenir study, which aims to show that putting an additional 3000 men in Paris on PrEP would lead to a 15% reduction in HIV diagnoses among men who have sex with men. Study participants could opt to take Truvada either daily or according to the event-driven schedule, and they could switch during the study. The study got 3057 men to participate. Only two men from the study tested positive and that was after they’d stopped taking the drug.